Loading
Ginkgo Bioworks Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 May 2024.
Ginkgo Bioworks Holdings, Inc.: what insiders have been doing
Ginkgo Bioworks Holdings, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Boston, United States, founded in 2008. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 43 filings came from 8 insiders.
No insider bought on the market over the period, while 4 insiders filed 12 sales totalling €2.3M. At €686k, the sale published on 13 April 2026 by Canton Barry is the largest of the period.
The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 43 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 4 purchases against 236 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 170.2 m USD and net income at -312.8 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
435
Thresholds
n/a
Buy Volume
€2M
4 ops. · all time
Sell Volume
€71M
236 ops. · all time
Who traded when
BuySaleCoen Steven P.8 sales
Barry Canton3 sales
Shetty Reshma P.3 sales
Christian O. Henry2 sales
Kelly Jason R2 sales
Analyst consensus: bullish or bearish?
Analysts rate Ginkgo Bioworks Holdings, Inc. Underperform (bearish), based on 2 analysts. Average price target: US$8.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,572 of 24,148 companies
26.7
score / 100
Value7
Quality47
FCF yld-26%
Earn yld-45%
EV/EBITDA·
ROE-60%
Gross mgn72%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.53
Analyst consensus
2 analystsUnderperform
US$5.00Target US$8.00(-31%)US$11.00
Income statement
RevenueUS$170.2M
Gross profitUS$123.2M72% margin
EBITDA-US$254.6M-150% margin
Net income-US$312.8M-219.6% margin
Valuation
PER (forward)-4.0x
P/Book1.7x
Beta1.80
Balance sheet & cash
Market capUS$776.4M
Total debtUS$439.9M
Free Cash Flow-US$178.7M
Debt / Equity96%
Profitability & ownership
ROE-59.9%
ROA-16.7%
% insiders4.4%
% institutions73.7%
Last declaration on 5 October 2026
Declarations435 total
2,403 shares@ US$15.000.0043% mcap10.1% of flowClass ASEC144:0001959173-26-007259
2,200 shares@ US$7.2933.3% of flowClass ASEC144:0001959173-26-007017
5,000 shares@ US$7.0810.2% of flowClass A Common StockSEC:0001628280-26-062239:0
5,000 shares@ US$7.08120.2% of flowClass ASEC144:0001959173-26-006973
156 sharesClass A Common StockSEC:0001628280-26-058939:1
587 sharesClass A Common StockSEC:0001628280-26-058939:0
330 shares@ US$6.9770.7% of flowClass A Common StockSEC:0001628280-26-058939:2
330 shares@ US$6.97720.7% of flowClass ASEC144:0001959173-26-006388
2,200 shares@ US$6.6630.1% of flowClass ASEC144:0001959173-26-006078
312 sharesClass A Common StockSEC:0001628280-26-048832:1
1,174 sharesClass A Common StockSEC:0001628280-26-048832:0
752 shares@ US$7.9031.8% of flowClass A Common StockSEC:0001628280-26-048832:2
752 shares@ US$7.90331.8% of flowClass ASEC144:0001959173-26-005273
2,200 shares@ US$8.0636.6% of flowClass ASEC144:0001959173-26-004504
307 shares@ US$8.3340.8% of flowClass A Common StockSEC:0001628280-26-038202:2
587 sharesClass A Common StockSEC:0001628280-26-038202:0
156 sharesClass A Common StockSEC:0001628280-26-038202:1
324 shares@ US$7.9520.8% of flowClass A Common StockSEC:0001628280-26-026038:2
587 sharesClass A Common StockSEC:0001628280-26-026038:0
156 sharesClass A Common StockSEC:0001628280-26-026038:1
33,171 shares@ US$6.41463.1% of flowClass A Common StockSEC:0001628280-26-025107:2
28,368 sharesClass A Common StockSEC:0001628280-26-025107:0
45,553 sharesClass A Common StockSEC:0001628280-26-025107:1
124,727 shares@ US$6.4344.1% of flowClass A Common StockSEC:0001628280-26-024929:1
251,786 sharesClass A Common StockSEC:0001628280-26-024929:0
25 of 435 declarations
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. is a U.S.-based biotechnology company listed on the NYSE in the United States under the ticker DNA. The company is headquartered in Boston, Massachusetts, at 27 Drydock Avenue. Founded in Boston in 2008 by MIT-affiliated scientists, Ginkgo was built around a mission to make biology easier to engineer by combining biological design, software, automation, and lab infrastructure into one platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1830214/000162828026012346/R11.htm))
Ginkgo’s business model is organized around two main operating areas. The first, Cell Engineering, provides biological R&D tools and services to commercial and government customers across multiple industries, including healthcare, agriculture, industrial applications, chemicals, and materials. The second, Biosecurity, provides services designed to identify, monitor, prevent, and mitigate biological threats. Importantly, Ginkgo does not primarily sell end products to consumers; instead, it monetizes its platform, technical expertise, data capabilities, and automation stack to help customers move biological programs forward more quickly. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1830214/000162828026012346/R11.htm))
Read moreShow less
From a competitive standpoint, Ginkgo positions itself as a platform company in synthetic biology, a field where integration across robotics, computation, organism design, and experimental execution can create meaningful differentiation. The company emphasizes its Foundry platform and newer “autonomous labs” offering, placing it at the intersection of biotechnology, lab automation, and AI-enabled scientific workflows. That positioning allows Ginkgo to serve private customers while also participating in U.S. government-funded programs. ([nasdaq.com](https://www.nasdaq.com/press-release/twist-bioscience-and-ginkgo-bioworks-revise-collaboration-2025-05-08))
Recent developments have been strategically significant. In 2025, Ginkgo announced several government-related contracts and partnerships, including work with ARPA-H and a BARDA BioMaP Consortium award, underscoring its exposure to U.S. public-sector health, biosecurity, and industrial-resilience initiatives. In May 2025, the company also revised its collaboration with Twist Bioscience. Most notably, in late February 2026, Ginkgo announced its full-year 2025 results and said it had agreed to sell its Biosecurity business to a consortium of investors, turning that unit into a standalone private company while Ginkgo concentrates capital and management attention on autonomous labs. ([nasdaq.com](https://www.nasdaq.com/press-release/ginkgo-bioworks-teams-partners-arpa-h-project-stabilize-pharmaceutical-supply-chains))
For investors, the key theme is execution: Ginkgo remains a growth-oriented, restructuring-stage platform company whose medium-term value depends on commercial scaling, improved economics, and the success of its strategic pivot toward autonomous laboratory offerings in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
